Citigroup
GBIO

Citigroup’s Generation Bio GBIO Stock Holding History

Citigroup’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-668
Closed -$4.09K – 6195
2025
Q3 		$4.09K Sell
668
-368
-36% -$1.91K ﹤0.01% 5288
2025
Q2 		$3.32K Sell
1,036
-2,443
-70% -$9.41K ﹤0.01% 5325
2025
Q1 		$14.1K Sell
3,479
-669
-16% -$4.7K ﹤0.01% 5149
2024
Q4 		$44K Buy
4,148
+436
+12% +$7.77K ﹤0.01% 5118
2024
Q3 		$91.7K Buy
3,712
+2,599
+234% +$68.7K ﹤0.01% 4803
2024
Q2 		$31.4K Buy
1,113
+262
+31% +$8.51K ﹤0.01% 4836
2024
Q1 		$34.6K Buy
851
+204
+32% +$4.8K ﹤0.01% 4815
2023
Q4 		$10.7K Buy
647
+563
+670% +$9.82K ﹤0.01% 5182
2023
Q3 		$3.19K Sell
84
-1,376
-94% -$65.2K ﹤0.01% 4841
2023
Q2 		$80.3K Buy
1,460
+1,392
+2,047% +$63.9K ﹤0.01% 4353
2023
Q1 		$2.92K Sell
68
-152
-69% -$7.35K ﹤0.01% 5043
2022
Q4 		$8.63K Sell
220
-30
-12% -$1.57K ﹤0.01% 4883
2022
Q3 		$13K Sell
250
-259
-51% -$16.2K ﹤0.01% 4897
2022
Q2 		$33K Sell
509
-1,483
-74% -$96.9K ﹤0.01% 4733
2022
Q1 		$146K Sell
1,992
-9,276
-82% -$537K ﹤0.01% 4241
2021
Q4 		$798K Buy
11,268
+4,885
+77% +$853K ﹤0.01% 3465
2021
Q3 		$1.6M Sell
6,383
-9,496
-60% -$2.27M ﹤0.01% 2713
2021
Q2 		$4.27M Buy
15,879
+3,844
+32% +$1.15M ﹤0.01% 2035
2021
Q1 		$3.42M Buy
12,035
+11,640
+2,947% +$3.73M ﹤0.01% 2099
2020
Q4 		$112K Buy
395
+336
+569% +$108K ﹤0.01% 5447
2020
Q3 		$18K Buy
+59
New +$14.1K ﹤0.01% 6265

Other funds holding GBIO

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citigroup's GBIO Position: Q4 2025 in Review

Citigroup sold out of Generation Bio (GBIO) in Q4 2025, closing a stake of 668 shares — an estimated $4.09K sold.

Citigroup first reported a position in GBIO in Q3 2020 and held it in 21 quarters. The position peaked at $4.27M in Q2 2021. 48 funds tracked by Wall St. Rank hold GBIO as of Q4 2025.

  • Citigroup reported no remaining Generation Bio position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 668 Generation Bio shares in Q4 2025, an estimated $4.09K.
  • Citigroup first reported a position in Generation Bio in Q3 2020 and held it in 21 quarters.
  • Citigroup's Generation Bio position peaked at $4.27M in Q2 2021.
  • 48 funds tracked by Wall St. Rank held Generation Bio as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.